4
Changes in Ownership
Adaptive Biotechnologies Corp Filed Acc 0001209191-20-049271
Chief Business Development Off sold 6,771 shares at an average $41.30 ($279,648)
- Chief Business Development Off acquired 6,771 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| BENZENO SHARON Chief Business Development Off | 2020-09-01 | Option exercise | +2,604 | $6.55 | $17,056 | 2,604 | D: show line 1 in the form |
| BENZENO SHARON Chief Business Development Off | 2020-09-01 | Option exercise | +2,604 | $6.55 | $17,056 | 5,208 | D: show line 2 in the form |
| BENZENO SHARON Chief Business Development Off | 2020-09-01 | Option exercise | +1,563 | $7.27 | $11,363 | 6,771 | D: show line 3 in the form |
| BENZENO SHARON Chief Business Development Off | 2020-09-01 | Sale | −6,471 | $41.28 | $267,123 | 300 | D: show line 4 in the form |
| BENZENO SHARON Chief Business Development Off | 2020-09-01 | Sale | −300 | $41.75 | $12,525 | 0 | D: show line 5 in the form |
| Open-market sales · 6,771 sh · avg $41.30 · $279,648 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| BENZENO SHARON Chief Business Development Off | 2020-09-01 | Option exercise · Stock Option (Right to Buy) | −2,604 | 36,459 | D: show line 6 in the form | |||||
| BENZENO SHARON Chief Business Development Off | 2020-09-01 | Option exercise · Stock Option (Right to Buy) | −2,604 | 65,105 | D: show line 7 in the form | |||||
| BENZENO SHARON Chief Business Development Off | 2020-09-01 | Option exercise · Common Stock (Right to Buy) | −1,563 | 43,750 | D: show line 8 in the form |
Loading xslF345X03/doc4.xml…